SHANDONG KEXING BIOPRODUCTS CO., LTD
Founded in 1997, Shandong Kexing Bioproducts integrates R&D, manufacture, and sales of biopharmaceuticals. Genzon Group and Shenzhen Kexing Biotech are its major stock holders.
The company develops recombinant gene drugs and micro-ecological drugs, to serve the clinical treatment needs of kidney diseases, tumor, and gastrointestinal diseases. It has become a leading player in China's biopharmaceutical industry.
The main products are as follows:
1. Recombinant human erythropoietin injection (rh-EPO),
2.Recombinant human granulocyte colony-stimulating factor injection (G-CSF/ Filgrastim),
3.Combined clostridium butyricum and bifidobacterium preparation, live